Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
HI-Bio
Biotech
Biogen CEO said no risky deals in 2023. Now he’s ready to be bold
While Biogen’s pharma peers are hunting for late-stage assets with little risk, CEO Chris Viehbacher wants to bring in more early-stage medicines.
Annalee Armstrong
Aug 1, 2024 10:34am
Biogen inks $1.15B HI-Bio buyout to expand in immunology
May 22, 2024 8:24am
Joe Biden reportedly chooses NIH head—Chutes & Ladders
Apr 21, 2023 9:30am
HI-Bio's expectations elevated by phase 2 autoimmune readouts
Apr 11, 2023 6:00am
HI-Bio launches with $120M and two therapies from MorphoSys
Nov 1, 2022 6:00am
